Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAP-1002 in Pulmonary Arterial Hypertension (ALPHA)
NCT03145298Phase 1Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Oct 2017
- Primary completion
- Jan 2023
- Modality
- Mesenchymal Stem Cells, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deramiocel in pulmonary arterial hypertension (PAH), sponsored by Cedars-Sinai Medical Center. Started Oct 2017; status: completed.
02
Drugs
deramiocel
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03145298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145298.